Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Gemcitabine + Cisplatin in MIBC
NCT07876817Phase 4Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Primary completion
- Jan 2029
01
Overview
A Phase 4 trial of durvalumab in muscle-invasive bladder cancer (MIBC), sponsored by AstraZeneca. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07876817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876817.